摘要
脑胶质瘤是一种常见的颅内原发恶性肿瘤,起源于神经胶质细胞,严重影响人类的健康。随着神经肿瘤分子的发展,异柠檬酸脱氢酶-1(isocitrate dehydrogenase,IDH1)已经成为目前胶质瘤分子标志物的研究热点。IDH1的突变引起2-羟基戊二酸(2-hydroxyglutaric acid,2-HG)异常增高,进一步导致DNA和组蛋白高甲基化,目前已经成为研究的潜在靶点,这一发现能够使胶质瘤的临床治疗获益。本文概述了突变型IDH1的功能,以及目前IDH1突变在胶质瘤发生机制中的作用。此外,还讨论了IDH1突变的胶质瘤的靶向治疗、免疫治疗及临床预后。
Brain glioma is a common primary intracranial malignant tumor,which originates from nerve glial cells and seriously affects human health.With the development of neurotumor molecules,isocitrate dehydrogenase(IDH1) has become a hot spot in the study of molecular markers of glioma.IDH1 mutation causes abnormal increase of 2-hydroxyglutaric acid(2-HG),further leading to DNA and histone hypermethylation,which has become a potential target for research,and this discovery can benefit the clinical treatment of glioma.This paper provides an overview of the function of mutant IDH1,and the role of IDH1 mutations in gliomagenesis.In addition,the targeted treatment,immunotherapy and clinical prognosis of IDH1 mutant glioma have been discussed.
作者
刘凯飞
张烨
陈一
朴浩哲
Liu Kaifei;Zhang Ye;Chen Yi;Piao Haozhe(Dalian Medical University,Liaoning Dalian 116044,China;Cancer Hospital of China Medical University,Liaoning Cancer Hospital&Institute,Liaoning Shenyang 110042,China)
出处
《现代肿瘤医学》
CAS
2019年第8期1454-1457,共4页
Journal of Modern Oncology
基金
辽宁省省直临床建设项目(编号:LNCCC-B04-2015)
辽宁省中央引导地方科技发展专项项目(编号:2017106014)
辽宁省重点研发计划指导计划项目(编号:2018225040)
关键词
异柠檬酸脱氢酶
胶质瘤
2-羟基戊二酸
靶向治疗
isocitrate dehydrogenase(IDH)
glioma
2-hydroxyglutaric acid(2-HG)
targeted therapy
